The Magazine for Sleep Professionals
Monday, November 9, 2026
Mount Sinai researchers have created an analytic tool using machine learning that can predict cardiovascular disease risk in millions of patients with obstructive sleep apnea, a serious sleep disorder, according to findings recently published in Communications Medicine. The team said their study is the first to provide estimates of whether […]
The American Academy of Sleep Medicine has introduced the Full PSG Autoscoring Certification Program, a new initiative that independently evaluates and certifies autoscoring software that interprets adult sleep stages and events from polysomnography data. The Full PSG Autoscoring Certification Program represents a significant expansion of the AASM’s earlier pilot initiative, which launched […]
Many more people work very early morning shifts than overnight ones, and a large proportion struggle with excessive sleepiness from shift work disorder, leading to problems with focus, performance and safety. A new clinical trial by investigators from Mass General Brigham found that the wake-promoting drug solriamfetol (Sunosi) helped early […]
Apnimed, Inc., announced that it has entered into a senior secured credit facility for up to $150 million with funds managed by HealthCare Royalty Partners (“HCRx”). The capital is expected to support commercial readiness activities and the planned U.S. launch of Apnimed’s lead product candidate, AD109, if approved by the […]
Even if you’re not one to make New Year’s resolutions, the start of a new year naturally invites reflection on what worked well last year, what needs to change, and what to leave behind. With that spirit of looking ahead in mind, SleepWorld Magazine conducted its inaugural Reader Tech Survey […]
As a sleep physician, one of the most frustrating realities I encounter is not a lack of diagnostic tools, but the barriers patients face in accessing them. Obstructive sleep apnea (OSA) is common, serious, and widely underdiagnosed. Estimates suggest that more than 30 million adults in the United States are […]
Alkermes plc, announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Alixorexton is the company’s novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development […]
On March 25, United States District Court Judge Rebecca L. Pennell sentenced Dr. Eric Edward Haeger, age 57, of Brewster, Washington, to one year and a day in federal prison followed by a one-year term of supervised release after Haeger pleaded guilty to adulterating and misbranding medical devices with the […]
Eisai Inc. announced today that screening for global Study E2086-G000-202 (Study 202) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT07493265. Study sites are also planned for Canada, China, Europe, Japan, and South Korea. Study 202 is a three-period, […]
Eli Lilly and Company and Centessa Pharmaceuticals plc, a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, announced a definitive agreement for Lilly to acquire Centessa. Centessa is advancing a pipeline of orexin receptor 2 (OX2R) agonists designed to […]
